Pub Date : 2024-01-01Epub Date: 2024-02-28DOI: 10.1159/000537992
Aida F Martinez, Zachary Tom, David W Hsia, Janine Vintch, Nathan Yee
Introduction: Pulmonary infections, such as tuberculosis, can result in numerous pleural complications including empyemas, pneumothoraces with broncho-pleural fistulas, and persistent air leak (PAL). While definitive surgical interventions are often initially considered, management of these complications can be particularly challenging if a patient has an active infection and is not a surgical candidate.
Case presentation: Autologous blood patch pleurodesis and endobronchial valve placement have both been described in remedying PALs effectively and safely. PALs due to broncho-pleural fistulas in active pulmonary disease are rare, and we present two such cases that were managed with autologous blood patch pleurodesis and endobronchial valves.
Conclusion: The two cases presented illustrate the complexities of PAL management and discuss the treatment options that can be applied to individual patients.
{"title":"Novel Insights from Clinical Practice Autologous Blood Patch Pleurodesis and Endobronchial Valves for Management of Persistent Air Leaks in Two Cases of Tuberculosis.","authors":"Aida F Martinez, Zachary Tom, David W Hsia, Janine Vintch, Nathan Yee","doi":"10.1159/000537992","DOIUrl":"10.1159/000537992","url":null,"abstract":"<p><strong>Introduction: </strong>Pulmonary infections, such as tuberculosis, can result in numerous pleural complications including empyemas, pneumothoraces with broncho-pleural fistulas, and persistent air leak (PAL). While definitive surgical interventions are often initially considered, management of these complications can be particularly challenging if a patient has an active infection and is not a surgical candidate.</p><p><strong>Case presentation: </strong>Autologous blood patch pleurodesis and endobronchial valve placement have both been described in remedying PALs effectively and safely. PALs due to broncho-pleural fistulas in active pulmonary disease are rare, and we present two such cases that were managed with autologous blood patch pleurodesis and endobronchial valves.</p><p><strong>Conclusion: </strong>The two cases presented illustrate the complexities of PAL management and discuss the treatment options that can be applied to individual patients.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"289-294"},"PeriodicalIF":3.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139991001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-03-08DOI: 10.1159/000536607
Sofie Breuls, Astrid Blondeel, Marieke Wuyts, Geert M Verleden, Robin Vos, Wim Janssens, Thierry Troosters, Heleen Demeyer
Introduction: Lung transplant recipients are often physically inactive and are at risk of developing comorbidities. We investigated whether objectively measured physical activity was associated with the prevalence of comorbidities.
Methods: Physical activity (accelerometry) and the presence of cardiovascular disease, symptoms of depression and anxiety, diabetes, dyslipidaemia, hypertension, lower extremity artery disease, muscle weakness, obesity, and osteoporosis were assessed in 108 lung transplant recipients. Patients were divided into four groups based on daily step count.
Results: A cohort of 108 patients (60 ± 7 years, 51% male, 20 ± 14 months since transplantation) was included. Active patients (>7,500 steps/day) had significantly fewer comorbidities (4 comorbidities) compared to severely inactive patients (<2,500 steps/day, 6 comorbidities), and muscle weakness and high symptoms of depression were less prevalent. Severely inactive patients had significantly more cardiovascular comorbidities compared to all other groups. No other significant differences were observed.
Conclusion: Physically active lung transplant recipients have fewer comorbidities, lower prevalence of muscle weakness, and fewer symptoms of depression compared to very inactive patients.
{"title":"The Association between Objectively Measured Physical Activity and the Prevalence of Comorbidities in Lung Transplant Recipients.","authors":"Sofie Breuls, Astrid Blondeel, Marieke Wuyts, Geert M Verleden, Robin Vos, Wim Janssens, Thierry Troosters, Heleen Demeyer","doi":"10.1159/000536607","DOIUrl":"10.1159/000536607","url":null,"abstract":"<p><strong>Introduction: </strong>Lung transplant recipients are often physically inactive and are at risk of developing comorbidities. We investigated whether objectively measured physical activity was associated with the prevalence of comorbidities.</p><p><strong>Methods: </strong>Physical activity (accelerometry) and the presence of cardiovascular disease, symptoms of depression and anxiety, diabetes, dyslipidaemia, hypertension, lower extremity artery disease, muscle weakness, obesity, and osteoporosis were assessed in 108 lung transplant recipients. Patients were divided into four groups based on daily step count.</p><p><strong>Results: </strong>A cohort of 108 patients (60 ± 7 years, 51% male, 20 ± 14 months since transplantation) was included. Active patients (>7,500 steps/day) had significantly fewer comorbidities (4 comorbidities) compared to severely inactive patients (<2,500 steps/day, 6 comorbidities), and muscle weakness and high symptoms of depression were less prevalent. Severely inactive patients had significantly more cardiovascular comorbidities compared to all other groups. No other significant differences were observed.</p><p><strong>Conclusion: </strong>Physically active lung transplant recipients have fewer comorbidities, lower prevalence of muscle weakness, and fewer symptoms of depression compared to very inactive patients.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"251-256"},"PeriodicalIF":3.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140050274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-09-14DOI: 10.1159/000541365
Yogita S Patel, Anthony A Gatti, Forough Farrokhyar, Feng Xie, Waël C Hanna
Introduction: Endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) for lung cancer staging is operator dependent, resulting in high rates of non-diagnostic lymph node (LN) samples. We hypothesized that an artificial intelligence (AI) algorithm can consistently and reliably predict nodal metastases from the ultrasound images of LNs when compared to pathology.
Methods: In this analysis of prospectively recorded B-mode images of mediastinal LNs during EBUS-TBNA, we used transfer learning to build an end-to-end ensemble of three deep neural networks (ResNet152V2, InceptionV3, and DenseNet201). Model hyperparameters were tuned, and the optimal version(s) of each model was trained using 80% of the images. A learned ensemble (multi-layer perceptron) of the optimal versions was applied to the remaining 20% of the images (Test Set). All predictions were compared to the final pathology from nodal biopsies and/or surgical specimen.
Results: A total of 2,569 LN images from 773 patients were used. The Training Set included 2,048 LNs, of which 70.02% were benign and 29.98% were malignant on pathology. The Testing Set included 521 LNs, of which 70.06% were benign and 29.94% were malignant on pathology. The final ensemble model had an overall accuracy of 80.63% (95% confidence interval [CI]: 76.93-83.97%), 43.23% sensitivity (95% CI: 35.30-51.41%), 96.91% specificity (95% CI: 94.54-98.45%), 85.90% positive predictive value (95% CI: 76.81-91.80%), 79.68% negative predictive value (95% CI: 77.34-81.83%), and AUC of 0.701 (95% CI: 0.646-0.755) for malignancy.
Conclusion: There now exists an AI algorithm which can identify nodal metastases based only on ultrasound images with good overall accuracy, specificity, and positive predictive value. Further optimization with larger sample sizes would be beneficial prior to clinical application.
{"title":"Artificial Intelligence Algorithm Can Predict Lymph Node Malignancy from Endobronchial Ultrasound Transbronchial Needle Aspiration Images for Non-Small Cell Lung Cancer.","authors":"Yogita S Patel, Anthony A Gatti, Forough Farrokhyar, Feng Xie, Waël C Hanna","doi":"10.1159/000541365","DOIUrl":"10.1159/000541365","url":null,"abstract":"<p><strong>Introduction: </strong>Endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) for lung cancer staging is operator dependent, resulting in high rates of non-diagnostic lymph node (LN) samples. We hypothesized that an artificial intelligence (AI) algorithm can consistently and reliably predict nodal metastases from the ultrasound images of LNs when compared to pathology.</p><p><strong>Methods: </strong>In this analysis of prospectively recorded B-mode images of mediastinal LNs during EBUS-TBNA, we used transfer learning to build an end-to-end ensemble of three deep neural networks (ResNet152V2, InceptionV3, and DenseNet201). Model hyperparameters were tuned, and the optimal version(s) of each model was trained using 80% of the images. A learned ensemble (multi-layer perceptron) of the optimal versions was applied to the remaining 20% of the images (Test Set). All predictions were compared to the final pathology from nodal biopsies and/or surgical specimen.</p><p><strong>Results: </strong>A total of 2,569 LN images from 773 patients were used. The Training Set included 2,048 LNs, of which 70.02% were benign and 29.98% were malignant on pathology. The Testing Set included 521 LNs, of which 70.06% were benign and 29.94% were malignant on pathology. The final ensemble model had an overall accuracy of 80.63% (95% confidence interval [CI]: 76.93-83.97%), 43.23% sensitivity (95% CI: 35.30-51.41%), 96.91% specificity (95% CI: 94.54-98.45%), 85.90% positive predictive value (95% CI: 76.81-91.80%), 79.68% negative predictive value (95% CI: 77.34-81.83%), and AUC of 0.701 (95% CI: 0.646-0.755) for malignancy.</p><p><strong>Conclusion: </strong>There now exists an AI algorithm which can identify nodal metastases based only on ultrasound images with good overall accuracy, specificity, and positive predictive value. Further optimization with larger sample sizes would be beneficial prior to clinical application.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"741-751"},"PeriodicalIF":3.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142294146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Serial follow-up with pulmonary function testing (PFT) and chest computed tomography (CT) after severe COVID-19 are recommended. As a result, many longitudinal studies have been published on COVID-19 of different grade of severity up to 1-year follow-up. Therefore, we aimed at a long-term observational study throughout 2 years after severe COVID-19.
Methods: Severe COVID-19 patients were consecutively recruited after hospital discharge between March and June 2020 and prospectively followed up for 24 months, with mMRC dyspnea scale and PFT at 6, 12, and 24 months. Chest CT was performed when clinically indicated.
Results: One hundred one patients enrolled completed the observational study. At 24 months, those with reduced total lung capacity (TLC) were 16%, associated with fibrotic ground glass opacity (GGO) and mMRC score >1, respectively, in 75% and 69% of them. At 24 months, those with a reduced diffusing capacity of the lung for CO were 41%, associated with fibrotic GGO and mMRC score >1, respectively, in 53% and 22% of them.
Conclusion: Two years after hospitalization for severe COVID-19, a non-negligible number of patients still suffer from "long COVID" due to respiratory damage.
{"title":"COVID-19 after 2 Years from Hospital Discharge: A Pulmonary Function and Chest Computed Tomography Follow-Up Study.","authors":"Simone Mennella, Cristiano Alicino, Marco Anselmo, Giuliana Carrega, Gianluca Ficarra, Luca Garra, Alessandro Gastaldo, Paola Gnerre, Flavia Lillo, Rodolfo Tassara, Anna Terrile, Manlio Milanese","doi":"10.1159/000535732","DOIUrl":"10.1159/000535732","url":null,"abstract":"<p><strong>Introduction: </strong>Serial follow-up with pulmonary function testing (PFT) and chest computed tomography (CT) after severe COVID-19 are recommended. As a result, many longitudinal studies have been published on COVID-19 of different grade of severity up to 1-year follow-up. Therefore, we aimed at a long-term observational study throughout 2 years after severe COVID-19.</p><p><strong>Methods: </strong>Severe COVID-19 patients were consecutively recruited after hospital discharge between March and June 2020 and prospectively followed up for 24 months, with mMRC dyspnea scale and PFT at 6, 12, and 24 months. Chest CT was performed when clinically indicated.</p><p><strong>Results: </strong>One hundred one patients enrolled completed the observational study. At 24 months, those with reduced total lung capacity (TLC) were 16%, associated with fibrotic ground glass opacity (GGO) and mMRC score >1, respectively, in 75% and 69% of them. At 24 months, those with a reduced diffusing capacity of the lung for CO were 41%, associated with fibrotic GGO and mMRC score >1, respectively, in 53% and 22% of them.</p><p><strong>Conclusion: </strong>Two years after hospitalization for severe COVID-19, a non-negligible number of patients still suffer from \"long COVID\" due to respiratory damage.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"22-31"},"PeriodicalIF":3.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139404142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-05-22DOI: 10.1159/000539281
Shirui Meng, Zechun Zeng, Huijuan Zuo, Jinwen Wang
Introduction: With a surge in the prevalence of coronavirus disease-2019 (COVID-19) in Beijing starting in October 2022, hospitalisation rates increased markedly. This study aimed to evaluate factors associated with in-hospital mortality in patients with COVID-19.
Methods: Using data from hospitalised patients, sex-based differences in clinical characteristics, in-hospital management, and in-hospital mortality among patients diagnosed with COVID-19 were evaluated. Predictive factors associated with mortality in 1,091 patients admitted to the Beijing Anzhen Hospital (Beijing, China) for COVID-19 between October 2022 and January 2023 were also evaluated.
Results: Data from 1,091 patients hospitalised with COVID-19 were included in the analysis. In-hospital mortality rates for male and female patients were 14.9% and 10.4%, respectively. Multifactorial logistic analysis indicated that lymphocyte percentage (LYM%) (odds ratio [OR] 0.863, 95% confidence interval [CI] 0.805-0.925; p < 0.001), uric acid (OR 1.004, 95% CI: 1.002-1.006; p = 0.001), and high-sensitivity C-reactive protein (OR 1.094, 95% CI: 1.012-1.183; p = 0.024) levels were independently associated with COVID-19-related in-hospital mortality. Among female patients, multifactorial analysis revealed that LYM% (OR 0.856, 95% CI: 0.796-0.920; p < 0.001), older age (OR 1.061, 95% CI: 1.020-1.103; p = 0.003), obesity (OR 2.590, 95% CI: 1.131-5.931; p = 0.024), and a high high-sensitivity troponin I level (OR 2.602, 95% CI: 1.157-5.853; p = 0.021) were risk factors for in-hospital mortality. Receiver operating characteristic (ROC) curve analysis, including area under the ROC curve, showed that the efficacy of LYM% in predicting in-hospital death was 0.800 (sensitivity, 63.2%; specificity, 83.2%) in male patients and 0.815 (sensitivity, 87.5%; specificity, 64.4%) in female patients.
Conclusion: LYM% is a consistent predictor of in-hospital mortality for both sexes. Older age and markers of systemic inflammation, myocardial injury, and metabolic dysregulation are also associated with a high mortality risk. These findings may help identify patients who require closer monitoring and tailored interventions to improve outcomes.
导言:自2022年10月起,随着冠状病毒病(COVID-19)在北京的流行,住院人数明显增加。本研究旨在评估与 COVID-19 患者院内死亡率相关的因素:方法:利用住院患者的数据,评估确诊为 COVID-19 的患者在临床特征、院内管理和院内死亡率方面的性别差异。此外,还对北京安贞医院(中国北京)在2022年10月至2023年1月期间收治的1091名COVID-19患者的死亡率相关预测因素进行了评估:分析纳入了1091名COVID-19住院患者的数据。男性和女性的院内死亡率分别为14.9%和10.4%。多因素逻辑分析显示,淋巴细胞百分比(LYM%)(几率比[OR] 0.863 [95% 置信区间(CI)0.805-0.925];P<0.001)、尿酸(OR 1.004 [95% CI 1.002-1.006];P=0.001)和高敏C反应蛋白(hs-CRP)(OR 1.094 [95% CI 1.012-1.183];P=0.024)与COVID-19的院内死亡率独立相关。在女性患者中,多因素分析显示,LYM%(OR 0.856 [95% CI 0.796-0.920];P<0.001)、年龄较大(OR 1.061 [95% CI 1.020-1.103];P=0.003)、肥胖(OR 2.590[95%CI1.131-5.931];P=0.024)、高敏肌钙蛋白 I 水平高(OR 2.602[95%CI 1.157-5.853];P=0.021)是院内死亡的危险因素。接收者操作特征(ROC)曲线分析显示,LYM%在预测男性院内死亡方面的有效性及其ROC曲线下面积(AUC)为0.800,敏感性为63.2%,特异性为83.2%。预测女性住院死亡的 AUC 为 0.815,灵敏度为 87.5%,特异度为 64.4%:结论:LYM%是预测男女住院死亡率的一致指标。结论:LYM%是男女患者院内死亡率的一致预测指标,年龄越大,全身炎症、心肌损伤和代谢失调的标记物越多,死亡率越高。这些发现有助于确定哪些患者需要更密切的监测和有针对性的干预,以改善预后。
{"title":"Sex Difference in Characteristics and Predictors of In-Hospital Mortality among Patients with COVID-19.","authors":"Shirui Meng, Zechun Zeng, Huijuan Zuo, Jinwen Wang","doi":"10.1159/000539281","DOIUrl":"10.1159/000539281","url":null,"abstract":"<p><strong>Introduction: </strong>With a surge in the prevalence of coronavirus disease-2019 (COVID-19) in Beijing starting in October 2022, hospitalisation rates increased markedly. This study aimed to evaluate factors associated with in-hospital mortality in patients with COVID-19.</p><p><strong>Methods: </strong>Using data from hospitalised patients, sex-based differences in clinical characteristics, in-hospital management, and in-hospital mortality among patients diagnosed with COVID-19 were evaluated. Predictive factors associated with mortality in 1,091 patients admitted to the Beijing Anzhen Hospital (Beijing, China) for COVID-19 between October 2022 and January 2023 were also evaluated.</p><p><strong>Results: </strong>Data from 1,091 patients hospitalised with COVID-19 were included in the analysis. In-hospital mortality rates for male and female patients were 14.9% and 10.4%, respectively. Multifactorial logistic analysis indicated that lymphocyte percentage (LYM%) (odds ratio [OR] 0.863, 95% confidence interval [CI] 0.805-0.925; p < 0.001), uric acid (OR 1.004, 95% CI: 1.002-1.006; p = 0.001), and high-sensitivity C-reactive protein (OR 1.094, 95% CI: 1.012-1.183; p = 0.024) levels were independently associated with COVID-19-related in-hospital mortality. Among female patients, multifactorial analysis revealed that LYM% (OR 0.856, 95% CI: 0.796-0.920; p < 0.001), older age (OR 1.061, 95% CI: 1.020-1.103; p = 0.003), obesity (OR 2.590, 95% CI: 1.131-5.931; p = 0.024), and a high high-sensitivity troponin I level (OR 2.602, 95% CI: 1.157-5.853; p = 0.021) were risk factors for in-hospital mortality. Receiver operating characteristic (ROC) curve analysis, including area under the ROC curve, showed that the efficacy of LYM% in predicting in-hospital death was 0.800 (sensitivity, 63.2%; specificity, 83.2%) in male patients and 0.815 (sensitivity, 87.5%; specificity, 64.4%) in female patients.</p><p><strong>Conclusion: </strong>LYM% is a consistent predictor of in-hospital mortality for both sexes. Older age and markers of systemic inflammation, myocardial injury, and metabolic dysregulation are also associated with a high mortality risk. These findings may help identify patients who require closer monitoring and tailored interventions to improve outcomes.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"480-487"},"PeriodicalIF":3.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141071032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-06-13DOI: 10.1159/000539573
Illaa Smesseim, Louis-Vincent Morin-Thibault, Felix J F Herth, James Tonkin, Pallav L Shah, Dirk-Jan Slebos, David T Koster, Chris Dickhoff, Johannes Marlene Andreas Daniels, Jouke Annema, Peter Bonta
Introduction: Persistent air leak (PAL) is associated with prolonged hospitalization, high morbidity and increased treatment costs. Conservative treatment consists of observation, chest tube drainage, and pleurodesis. Guidelines recommend surgical evaluation if air leak does not respond after 3-5 days. One-way endobronchial valves (EBV) have been proposed as a treatment option for patients with PAL in which surgical treatment is not feasible, high risk or has failed. We aimed to provide a comprehensive overview of reported EBV use for PAL and issue best practice recommendations based on multicenter experience.
Methods: We conducted a retrospective observational case-series study at four different European academic hospitals and provided best practice recommendations based on our experience. A systematic literature review was performed to summarize the current knowledge on EBV in PAL.
Results: We enrolled 66 patients, male (66.7%), median age 59.5 years. The most common underlying lung disease was chronic obstructive pulmonary disease (39.4%) and lung cancer (33.3%). The median time between pneumothorax and valve placement was 24.5 days (interquartile range: 14.0-54.3). Air leak resolved in 40/66 patients (60.6%) within 30 days after EBV treatment. Concerning safety outcome, no procedure-related mortality was reported and complication rate was low (6.1%). Five patients (7.6%) died in the first 30 days after intervention.
Conclusion: EBV placement is a treatment option in patients with PAL. In this multicenter case-series of high-risk patients not eligible for lung surgery, we show that EBV placement resulted in air leak resolution in 6 out of 10 patients with a low complication rate. Considering the minimally invasive nature of EBV to treat PAL as opposed to surgery, further research should investigate if EBV treatment should be expanded in low to intermediate risk PAL patients.
导言:持续性气漏(PAL)与住院时间长、发病率高和治疗费用增加有关。保守治疗包括观察、胸腔管引流和胸膜穿刺术。如果气漏在 3-5 天后仍无反应,指南建议进行手术评估。单向支气管内瓣膜(EBV)已被提议作为一种治疗方案,用于手术治疗不可行、高风险或失败的 PAL 患者。我们的目的是全面概述 EBV 用于 PAL 的报道,并根据多中心经验提出最佳实践建议。方法 我们在四家不同的欧洲学术医院开展了一项回顾性观察病例系列研究,并根据我们的经验提出了最佳实践建议。我们还进行了系统的文献综述,总结了目前有关 PAL 中 EBV 的知识。结果 我们共招募了 66 名患者,男性(66.7%),中位年龄为 59.5 岁。最常见的肺部疾病是慢性阻塞性肺病(39.4%)和肺癌(33.3%)。气胸与瓣膜置入之间的中位时间为 24.5 天(IQR:14.0-54.3)。40/66的患者(60.6%)在接受支气管内瓣膜治疗后30天内解决了漏气问题。在安全性方面,没有与手术相关的死亡率报告,并发症发生率较低(6.1%)。5 名患者(7.6%)在介入治疗后 30 天内死亡。结论 EBV 置入术是治疗持续性气漏 (PAL) 患者的一种选择。在这一多中心病例系列中,我们对不符合肺部手术条件的高风险患者进行了研究,结果显示,10 名患者中有 6 名通过 EBV 置入术解决了气漏问题,且并发症发生率较低。考虑到 EBV 治疗 PAL 的微创性优于手术,进一步的研究应探讨是否应将 EBV 治疗扩大到中低风险的 PAL 患者。
{"title":"Endobronchial Valves in Treatment of Persistent Air Leak: European Case-Series Study and Best Practice Recommendations - From an Expert Panel.","authors":"Illaa Smesseim, Louis-Vincent Morin-Thibault, Felix J F Herth, James Tonkin, Pallav L Shah, Dirk-Jan Slebos, David T Koster, Chris Dickhoff, Johannes Marlene Andreas Daniels, Jouke Annema, Peter Bonta","doi":"10.1159/000539573","DOIUrl":"10.1159/000539573","url":null,"abstract":"<p><strong>Introduction: </strong>Persistent air leak (PAL) is associated with prolonged hospitalization, high morbidity and increased treatment costs. Conservative treatment consists of observation, chest tube drainage, and pleurodesis. Guidelines recommend surgical evaluation if air leak does not respond after 3-5 days. One-way endobronchial valves (EBV) have been proposed as a treatment option for patients with PAL in which surgical treatment is not feasible, high risk or has failed. We aimed to provide a comprehensive overview of reported EBV use for PAL and issue best practice recommendations based on multicenter experience.</p><p><strong>Methods: </strong>We conducted a retrospective observational case-series study at four different European academic hospitals and provided best practice recommendations based on our experience. A systematic literature review was performed to summarize the current knowledge on EBV in PAL.</p><p><strong>Results: </strong>We enrolled 66 patients, male (66.7%), median age 59.5 years. The most common underlying lung disease was chronic obstructive pulmonary disease (39.4%) and lung cancer (33.3%). The median time between pneumothorax and valve placement was 24.5 days (interquartile range: 14.0-54.3). Air leak resolved in 40/66 patients (60.6%) within 30 days after EBV treatment. Concerning safety outcome, no procedure-related mortality was reported and complication rate was low (6.1%). Five patients (7.6%) died in the first 30 days after intervention.</p><p><strong>Conclusion: </strong>EBV placement is a treatment option in patients with PAL. In this multicenter case-series of high-risk patients not eligible for lung surgery, we show that EBV placement resulted in air leak resolution in 6 out of 10 patients with a low complication rate. Considering the minimally invasive nature of EBV to treat PAL as opposed to surgery, further research should investigate if EBV treatment should be expanded in low to intermediate risk PAL patients.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"544-562"},"PeriodicalIF":3.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141318115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-06-27DOI: 10.1159/000539974
Mingming Deng, Run Tong, Jieru Lin, Yiding Bian, Guowu Zhou, Felix J F Herth, Gang Hou
Introduction: Subglottic stenosis, manifested by granulation tissue hyperplasia, is challenging and requires multiple repeated treatments and stent maintenance at times. Corticosteroids prevent severe subglottic stenosis development owing to their antifibrotic and anti-inflammatory properties. Submucosal injection of glucocorticoids, a useful adjuvant therapeutic method, improves the mean interval between endoscopic procedures and reduces airway restenosis risks.
Case presentation: We report a rare case of a man with complex subglottic stenosis who underwent balloon dilatation combined with cryotherapy, stent placement, and adjuvant submucosal triamcinolone injection. The drug was injected efficiently and safely into the submucosal layer under percutaneous ultrasound guidance, and subglottic stenosis was well-controlled at a low cost.
Conclusion: POCUS-guided medication injections may be a useful adjuvant medical therapy for subglottic stenosis.
{"title":"Percutaneous Ultrasound-Guided Medication Injection: A Potential Technique for Subglottic Stenosis.","authors":"Mingming Deng, Run Tong, Jieru Lin, Yiding Bian, Guowu Zhou, Felix J F Herth, Gang Hou","doi":"10.1159/000539974","DOIUrl":"10.1159/000539974","url":null,"abstract":"<p><strong>Introduction: </strong>Subglottic stenosis, manifested by granulation tissue hyperplasia, is challenging and requires multiple repeated treatments and stent maintenance at times. Corticosteroids prevent severe subglottic stenosis development owing to their antifibrotic and anti-inflammatory properties. Submucosal injection of glucocorticoids, a useful adjuvant therapeutic method, improves the mean interval between endoscopic procedures and reduces airway restenosis risks.</p><p><strong>Case presentation: </strong>We report a rare case of a man with complex subglottic stenosis who underwent balloon dilatation combined with cryotherapy, stent placement, and adjuvant submucosal triamcinolone injection. The drug was injected efficiently and safely into the submucosal layer under percutaneous ultrasound guidance, and subglottic stenosis was well-controlled at a low cost.</p><p><strong>Conclusion: </strong>POCUS-guided medication injections may be a useful adjuvant medical therapy for subglottic stenosis.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"583-586"},"PeriodicalIF":3.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141478361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-07-18DOI: 10.1159/000540297
Simon Alexander Krooss, Isabel Klefenz, Michael Ott, Frank Klawonn, Daniela Leitl, Tessa Schneeberger, Inga Jarosch, Claus Franz Vogelmeier, Marek Lommatzsch, Rainer Gloeckl, Andreas Rembert Koczulla
Introduction: SARS-CoV-2 infections can result in a broad spectrum of symptoms from mild to life-threatening. Long-term consequences on lung function are not well understood yet.
Methods: In our study, we have examined 134 post-COVID patients (aged 54.83 ± 14.4 years) with dyspnea on exertion as a leading symptom 6 weeks to 24 months after a SARS-CoV-2 infection for bronchodilator responsiveness during their stay in our pulmonary rehabilitation clinic.
Results: Prior to bronchial dilation, 6 out of 134 patients (4.47%) presented an FEV1/FVC ratio below lower limit of normal (Z-score = -1.645) indicative of an obstructive airway disease. Following inhalation of a β2-adrenergic agonist we measured a mean FEV1 increase of 181.5 mL in our cohort, which was significantly elevated compared to a historical control group (ΔFEV1 = 118 mL). 28.7% of the patients showed an increase greater than 200 mL and 12% displayed a significant bronchodilation response (>200 mL ΔFEV1 and >12% FEV1 increase). Interestingly, no significant difference in bronchial dilation effect was observed when comparing patients hospitalized and those non-hospitalized during the course of their SARS-CoV-2 infection.
Conclusion: Our data provide evidence for increased prevalence of obstructive ventilatory defects and increased bronchodilator responsiveness in patients with persisting symptoms after COVID-19. Depending on the extent of this complication, post-COVID patients may benefit from an adapted β2-inhalation therapy including subsequent reevaluation.
{"title":"Bronchodilator Response in Post-COVID-19 Patients Undergoing Pulmonary Rehabilitation.","authors":"Simon Alexander Krooss, Isabel Klefenz, Michael Ott, Frank Klawonn, Daniela Leitl, Tessa Schneeberger, Inga Jarosch, Claus Franz Vogelmeier, Marek Lommatzsch, Rainer Gloeckl, Andreas Rembert Koczulla","doi":"10.1159/000540297","DOIUrl":"10.1159/000540297","url":null,"abstract":"<p><strong>Introduction: </strong>SARS-CoV-2 infections can result in a broad spectrum of symptoms from mild to life-threatening. Long-term consequences on lung function are not well understood yet.</p><p><strong>Methods: </strong>In our study, we have examined 134 post-COVID patients (aged 54.83 ± 14.4 years) with dyspnea on exertion as a leading symptom 6 weeks to 24 months after a SARS-CoV-2 infection for bronchodilator responsiveness during their stay in our pulmonary rehabilitation clinic.</p><p><strong>Results: </strong>Prior to bronchial dilation, 6 out of 134 patients (4.47%) presented an FEV1/FVC ratio below lower limit of normal (Z-score = -1.645) indicative of an obstructive airway disease. Following inhalation of a β2-adrenergic agonist we measured a mean FEV1 increase of 181.5 mL in our cohort, which was significantly elevated compared to a historical control group (ΔFEV1 = 118 mL). 28.7% of the patients showed an increase greater than 200 mL and 12% displayed a significant bronchodilation response (>200 mL ΔFEV1 and >12% FEV1 increase). Interestingly, no significant difference in bronchial dilation effect was observed when comparing patients hospitalized and those non-hospitalized during the course of their SARS-CoV-2 infection.</p><p><strong>Conclusion: </strong>Our data provide evidence for increased prevalence of obstructive ventilatory defects and increased bronchodilator responsiveness in patients with persisting symptoms after COVID-19. Depending on the extent of this complication, post-COVID patients may benefit from an adapted β2-inhalation therapy including subsequent reevaluation.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"622-629"},"PeriodicalIF":3.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11446304/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-10-24DOI: 10.1159/000542018
Didier Lardinois, Kathleen Jahn, Aljaz Hojski, Spasenija Savic Prince, Nikolay Tsvetkov, Zeljko Djakovic, Helga Bachmann, Michael Tamm
Introduction: This case report addresses the complexity of management of air leak and persisting infection in polymorbid patients.
Case presentation: A 56-year-old former marble mason presented with major hemoptysis. Chest CT revealed severe silicosis and pneumonia with an abscess in the right lower lobe and a pulmonary artery pseudoaneurysm. An open lower bilobectomy with empyema debridement was performed, and the posterior upper lobe segment was covered with a serratus anterior muscle flap. The second examination revealed persistent air leakage from the infected posterior upper lobe segment and necrosis of the muscle flap. Atypical resection of this segment was performed, and the surface of the lower part of the remnant lung was covered with a fat flap and then the omentum. The patient was discharged but was readmitted 2 weeks later due to empyema. During reoperation, a persistent infection in the remnant posterior upper lobe segment was observed in addition to a bronchopleural fistula. The only possible surgery that would cure the patient was right completion pneumonectomy. To avoid this high-risk operation, an endobronchial valve was placed intraoperatively in the posterior segment bronchus, leading to closure of the fistula and resolution of the infection. The patient recovered well and was discharged 10 days later. At the 1-year follow-up, the patient was free of symptoms and reported a good quality of life.
Conclusion: This case is an excellent example of successful cooperation between an interventional pulmonologist and a thoracic surgeon to avoid right pneumonectomy in a polymorbid patient.
{"title":"Successful Endobronchial Valve Placement in the Treatment of Persistent Bronchopleural Fistula and Empyema Allows the Avoidance of Right Completion Pneumonectomy.","authors":"Didier Lardinois, Kathleen Jahn, Aljaz Hojski, Spasenija Savic Prince, Nikolay Tsvetkov, Zeljko Djakovic, Helga Bachmann, Michael Tamm","doi":"10.1159/000542018","DOIUrl":"10.1159/000542018","url":null,"abstract":"<p><strong>Introduction: </strong>This case report addresses the complexity of management of air leak and persisting infection in polymorbid patients.</p><p><strong>Case presentation: </strong>A 56-year-old former marble mason presented with major hemoptysis. Chest CT revealed severe silicosis and pneumonia with an abscess in the right lower lobe and a pulmonary artery pseudoaneurysm. An open lower bilobectomy with empyema debridement was performed, and the posterior upper lobe segment was covered with a serratus anterior muscle flap. The second examination revealed persistent air leakage from the infected posterior upper lobe segment and necrosis of the muscle flap. Atypical resection of this segment was performed, and the surface of the lower part of the remnant lung was covered with a fat flap and then the omentum. The patient was discharged but was readmitted 2 weeks later due to empyema. During reoperation, a persistent infection in the remnant posterior upper lobe segment was observed in addition to a bronchopleural fistula. The only possible surgery that would cure the patient was right completion pneumonectomy. To avoid this high-risk operation, an endobronchial valve was placed intraoperatively in the posterior segment bronchus, leading to closure of the fistula and resolution of the infection. The patient recovered well and was discharged 10 days later. At the 1-year follow-up, the patient was free of symptoms and reported a good quality of life.</p><p><strong>Conclusion: </strong>This case is an excellent example of successful cooperation between an interventional pulmonologist and a thoracic surgeon to avoid right pneumonectomy in a polymorbid patient.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"777-781"},"PeriodicalIF":3.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142506866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-01-29DOI: 10.1159/000535704
Maximilian Wollsching-Strobel, Karsten Stannek, Daniel Sebastian Majorski, Friederike Sophie Magnet, Doreen Kroppen, Melanie Patricia Berger, Maximilian Zimmermann, Wolfram Windisch, Sarah Bettina Stanzel
The treatment of patients with COPD and chronic hypercapnic respiratory failure using noninvasive ventilation (NIV) is well established. A "deventilation syndrome" (DVS) has been described as acute dyspnea after cessation of NIV therapy. A systematic scoping review reporting according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) searching Embase was conducted in September 2021. A final manual search followed in February 2023. Literature synthesis was blinded using Rayyan by three different reviewers. A total of 2,009 studies were screened. Five studies met the eligibility criteria. Four articles presented original data. Three articles examined potential treatment options. Three studies were prospective; none were randomized. A total of 122 patients were included. DVS was defined differently in all studies. Seventy-four patients were identified to suffer from DVS (48 controls). Patients were evaluated by blood gas analysis, transcutaneous TcCO2 measurement, spirometry, whole-body plethysmography, respiratory muscle assessments, diaphragmatic electromyography, ultrasound, 6-min walk test, polysomnography, and questionnaires. Treatment approaches studied were minimization of "patient-ventilator asynchrony" (PVA) and use of pursed- lip breathing ventilation. Pathophysiological mechanisms discussed were PVA, high inspiratory positive airway pressure, hyperinflation, respiratory muscle impairment, and increased respiratory rates. Compared with controls, patients with DVS appeared to suffer from more severe airway obstruction, hyperinflation, and PaCO2 retention; worse exercise test scores; and poorer quality of life. The available evidence does not allow for definite conclusions about pathophysiological mechanisms, ethology, or therapeutic options. Future studies should focus on a consistent definition and possible pathomechanisms.
{"title":"Deventilation Syndrome in COPD Patients Receiving Long-Term Home Noninvasive Ventilation: A Systematic Scoping Review.","authors":"Maximilian Wollsching-Strobel, Karsten Stannek, Daniel Sebastian Majorski, Friederike Sophie Magnet, Doreen Kroppen, Melanie Patricia Berger, Maximilian Zimmermann, Wolfram Windisch, Sarah Bettina Stanzel","doi":"10.1159/000535704","DOIUrl":"10.1159/000535704","url":null,"abstract":"<p><p>The treatment of patients with COPD and chronic hypercapnic respiratory failure using noninvasive ventilation (NIV) is well established. A \"deventilation syndrome\" (DVS) has been described as acute dyspnea after cessation of NIV therapy. A systematic scoping review reporting according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) searching Embase was conducted in September 2021. A final manual search followed in February 2023. Literature synthesis was blinded using Rayyan by three different reviewers. A total of 2,009 studies were screened. Five studies met the eligibility criteria. Four articles presented original data. Three articles examined potential treatment options. Three studies were prospective; none were randomized. A total of 122 patients were included. DVS was defined differently in all studies. Seventy-four patients were identified to suffer from DVS (48 controls). Patients were evaluated by blood gas analysis, transcutaneous TcCO2 measurement, spirometry, whole-body plethysmography, respiratory muscle assessments, diaphragmatic electromyography, ultrasound, 6-min walk test, polysomnography, and questionnaires. Treatment approaches studied were minimization of \"patient-ventilator asynchrony\" (PVA) and use of pursed- lip breathing ventilation. Pathophysiological mechanisms discussed were PVA, high inspiratory positive airway pressure, hyperinflation, respiratory muscle impairment, and increased respiratory rates. Compared with controls, patients with DVS appeared to suffer from more severe airway obstruction, hyperinflation, and PaCO2 retention; worse exercise test scores; and poorer quality of life. The available evidence does not allow for definite conclusions about pathophysiological mechanisms, ethology, or therapeutic options. Future studies should focus on a consistent definition and possible pathomechanisms.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"60-69"},"PeriodicalIF":3.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139576617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}